Company news

Idorsia Ltd. news in 2026

Idorsia Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance

October 29, 2026

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists

October 29, 2026

Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera

October 28, 2026

Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026

October 23, 2026

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

August 11, 2026

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

July 30, 2026

Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant

July 27, 2026

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

July 23, 2026

Idorsia appoints Roland Wandeler as Chief Executive Officer

July 1, 2026

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

June 26, 2026

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

June 9, 2026

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

June 1, 2026

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

June 1, 2026

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

May 6, 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

April 28, 2026

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

April 10, 2026

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

April 9, 2026

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

March 30, 2026

Idorsia announces the nomination of three candidates for election to the Board of Directors

March 24, 2026

Idorsia announces management change

March 16, 2026

Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink

March 10, 2026

Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026

February 26, 2026

Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call

February 12, 2026

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

February 6, 2026

Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium

January 30, 2026

Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America

January 28, 2026

Idorsia to present at J.P. Morgan 2026 Healthcare Conference

January 12, 2026

Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease

January 12, 2026

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

January 6, 2026

Idorsia’s daridorexant in women during menopausal transition age with insomnia

January 5, 2026

Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension

January 5, 2026

Calls in 2026

Decks in 2026